Hearing Loss Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight
' Hearing Loss Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.
The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hearing Loss Pipeline Report:
Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years.
Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Hearing Loss treatment
Emerging Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.
In February 2025, Sound Pharmaceuticals is excited to share that it will deliver four presentations at the upcoming Association for Research in Otolaryngology MidWinter Meeting. One of the key presentations, titled "The Development of SPI-1005 for the Treatment of Hearing Loss and Tinnitus," will be featured at the Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium. Organized by the Defense Health Agency (DHA) Hearing Center of Excellence (HCE) committee, this symposium will offer an in-depth review of investigational treatments aimed at preventing hearing loss and promoting hearing restoration.
In January 2025, US-based dermatology biopharma Eirion Therapeutics reported positive findings from its first-in-human, double-blind, placebo-controlled study of its topical treatment for age-related hair loss, demonstrating a six-fold increase in hair count over placebo. ET-02, the company's most advanced therapy for androgenic alopecia, was evaluated in a trial involving 24 male patients across three US sites, successfully meeting its primary safety and tolerability endpoints. Additionally, Eirion Therapeutics is advancing a preclinical oral version of ET-02, further expanding its pipeline for hair loss treatments.
In August 2024, Pelage Pharmaceuticals, a clinical-stage company specializing in regenerative medicine for hair loss, commenced its Phase 2a clinical trial for PP405, a novel topical small molecule aimed at treating androgenetic alopecia (pattern baldness). The first patients have been dosed, and the study will evaluate the drug's safety and effectiveness. The trial plans to enroll 60 men and women, with PP405 designed to activate dormant hair follicle stem cells, promoting hair growth
Hearing Loss Overview
Hearing Loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.
Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:
ACOU085: Acousia Therapeutics
Cochlear Hair Cell Regeneration: Decibel Therapeutics
HY01: Suzhou Pharmaceutical Technology Co.,Ltd
AC102: AudioCure Pharma GmbH
SENS-401: Sensorion
Hearing Loss Route of Administration
Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Hearing Loss Molecule Type
Hearing Loss Products have been categorized under various Molecule types, such as
Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Hearing Loss Pipeline Therapeutics Assessment
Hearing Loss Assessment by Product Type
Hearing Loss By Stage and Product Type
Hearing Loss Assessment by Route of Administration
Hearing Loss By Stage and Route of Administration
Hearing Loss Assessment by Molecule Type
Hearing Loss by Stage and Molecule Type
DelveInsight's Hearing Loss Report covers around 35+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Some of the key companies in the Hearing Loss Therapeutics Market include:
Key companies developing therapies for Hearing Loss are - Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.
Hearing Loss Pipeline Analysis:
The Hearing Loss pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.
Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hearing Loss drugs and therapies
Hearing Loss Pipeline Market Drivers
Rise in the Incidence of Hearing Loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Hearing Loss Market.
Hearing Loss Pipeline Market Barriers
However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Hearing Loss Market growth.
Scope of Hearing Loss Pipeline Drug Insight
Table of Contents
1. Hearing Loss Report Introduction
2. Hearing Loss Executive Summary
3. Hearing Loss Overview
4. Hearing Loss- Analytical Perspective In-depth Commercial Assessment
5. Hearing Loss Pipeline Therapeutics
6. Hearing Loss Late Stage Products (Phase II/III)
7. Hearing Loss Mid Stage Products (Phase II)
8. Hearing Loss Early Stage Products (Phase I)
9. Hearing Loss Preclinical Stage Products
10. Hearing Loss Therapeutics Assessment
11. Hearing Loss Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hearing Loss Key Companies
14. Hearing Loss Key Products
15. Hearing Loss Unmet Needs
16 . Hearing Loss Market Drivers and Barriers
17. Hearing Loss Future Perspectives and Conclusion
18. Hearing Loss Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Source: Sarepta Therapeutics, Inc.
Globe and Mail
2 days ago
- Globe and Mail
CAR T-Cell Therapy for Multiple Myeloma Pipeline Experiences Rapid Expansion as Over 5+ Leading Companies Advance Novel Therapies
DelveInsight's, 'CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2025,' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the CAR T-Cell Therapy for Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy for Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Dive into DelveInsight's comprehensive report today! @ CAR T-Cell Therapy for Multiple Myeloma Pipeline Outlook Key Takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report In July 2025, Janssen Research & Development LLC announced a study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). DelveInsight's CAR T-Cell Therapy for Multiple Myeloma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for CAR T-Cell Therapy for Multiple Myeloma treatment. The leading CAR T-Cell Therapy for Multiple Myeloma Companies such as Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. Promising CART-Cell Therapy for Multiple Myeloma Pipeline Therapies such as Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. Stay ahead with the most recent pipeline outlook for CAR T-Cell Therapy for Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ CAR T-Cell Therapy for Multiple Myeloma Treatment Drugs CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Profile Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the multiple myeloma treatment. JNJ-68284528: Janssen Biotech Janssen's drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status. The CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma Treatment. CAR T-Cell Therapy for Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. CAR T-Cell Therapy for Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market Explore groundbreaking therapies and clinical trials in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New CAR T-Cell Therapy for Multiple Myeloma Drugs CAR T-Cell Therapy for Multiple Myeloma Companies Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type CAR T-Cell Therapy for Multiple Myeloma Products have been categorized under various Molecule types such as Small molecules Natural metabolites Monoclonal antibodies Product Type Unveil the future of CAR T-Cell Therapy for Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ CAR T-Cell Therapy for Multiple Myeloma Market Drivers and Barriers Scope of the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Coverage- Global CAR T-Cell Therapy for Multiple Myeloma Companies- Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CART-Cell Therapy for Multiple Myeloma Pipeline Therapies- Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on CAR T-Cell Therapy for Multiple Myeloma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ CAR T-Cell Therapy for Multiple Myeloma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary CAR T-Cell Therapy for Multiple Myeloma: Overview Pipeline Therapeutics Therapeutic Assessment CAR T-Cell Therapy for Multiple Myeloma – DelveInsight's Analytical Perspective In-depth Commercial Assessment CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals Early Stage Products (Phase I) PHE 885: Novartis Drug profiles in the detailed report….. Pre-clinical Stage JNJ-68284528: Janssen Biotech Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products CAR T-Cell Therapy for Multiple Myeloma Key Companies CAR T-Cell Therapy for Multiple Myeloma Key Products CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion CAR T-Cell Therapy for Multiple Myeloma Analyst Views CAR T-Cell Therapy for Multiple Myeloma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
4 days ago
- Globe and Mail
Advanced Ovarian Cancer Clinical Trial Pipeline Spotlight: 50+ Companies Racing to Develop Safe and Effective Therapies
DelveInsight's, 'Advanced Ovarian Cancer Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Advanced Ovarian Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Advanced Ovarian Cancer Pipeline Outlook Report Key Takeaways from the Advanced Ovarian Cancer Pipeline Report In July 2025, AstraZeneca announced a study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated. In July 2025, CanariaBio Inc. announced a study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment. In July 2025, Incyte Corporation conducted a study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU. DelveInsight's Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment. The leading Advanced Ovarian Cancer Companies such as OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Promising Advanced Ovarian Cancer Pipeline Therapies such as Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Discover how the Advanced Ovarian Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Advanced Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Ovarian Cancer Clinical Trials and Studies Advanced Ovarian Cancer Emerging Drugs Profile Oregovomab: OncoQuest Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Stenoparib: Allarity Therapeutics Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome. DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2). The Advanced Ovarian Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment. Advanced Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market. Get a detailed analysis of the latest innovations in the Advanced Ovarian Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Advanced Ovarian Cancer Unmet Needs Advanced Ovarian Cancer Companies OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Advanced Ovarian Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Advanced Ovarian Cancer Therapies and key Developments @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Advanced Ovarian Cancer Pipeline Report Coverage- Global Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced Ovarian Cancer Pipeline Therapies- Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Advanced Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Advanced Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Advanced Ovarian Cancer drug development? Find out in DelveInsight's exclusive Advanced Ovarian Cancer Pipeline Report—access it now! @ Advanced Ovarian Cancer Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Advanced ovarian cancer: Overview Pipeline Therapeutics Therapeutic Assessment Advanced ovarian cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Advanced ovarian cancer Collaboration Deals Late Stage Products (Phase III) Oregovomab: OncoQuest Drug profiles in the detailed report….. Mid Stage Products (Phase II) Stenoparib - Allarity Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DS-6000a: Daiichi Sankyo Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Advanced ovarian cancer Key Companies Advanced ovarian cancer Key Products Advanced ovarian cancer- Unmet Needs Advanced ovarian cancer- Market Drivers and Barriers Advanced ovarian cancer- Future Perspectives and Conclusion Advanced ovarian cancer Analyst Views Advanced ovarian cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth Curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
